127 related articles for article (PubMed ID: 1660693)
1. Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours.
Kumar S; Hand PH; Marsden HB; Kumar P; Thor A
Anticancer Res; 1991; 11(4):1657-62. PubMed ID: 1660693
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas.
Mizukami Y; Nonomura A; Noguchi M; Taniya T; Koyasaki N; Saito Y; Hashimoto T; Matsubara F; Yanaihara N
Anticancer Res; 1991; 11(4):1485-94. PubMed ID: 1660689
[TBL] [Abstract][Full Text] [Related]
3. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
[TBL] [Abstract][Full Text] [Related]
4. Expression of the 21,000 molecular weight ras protein in a spectrum of benign and malignant human mammary tissues.
Ohuchi N; Thor A; Page DL; Hand PH; Halter SA; Schlom J
Cancer Res; 1986 May; 46(5):2511-9. PubMed ID: 3084069
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of Harvey ras p21 enhanced expression in human breast and colon carcinomas.
Hand PH; Vilasi V; Thor A; Ohuchi N; Schlom J
J Natl Cancer Inst; 1987 Jul; 79(1):59-65. PubMed ID: 3298786
[TBL] [Abstract][Full Text] [Related]
6. Ras p21 expression in nephroblastoma group tumors.
Aoki I; Yanoma S; Misugi K; Sasaki Y; Kikyo S
Acta Pathol Jpn; 1987 Dec; 37(12):1903-7. PubMed ID: 2833061
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical study of ras p21 expression in human gastric cancers and benign lesions].
Nakajima K
Hokkaido Igaku Zasshi; 1987 Jul; 62(4):573-80. PubMed ID: 3315926
[TBL] [Abstract][Full Text] [Related]
9. Advances in cancer biomarkers as applied to chemical exposures: the ras oncogene and p21 protein and pulmonary carcinogenesis.
Brandt-Rauf PW
J Occup Med; 1991 Sep; 33(9):951-5. PubMed ID: 1744743
[TBL] [Abstract][Full Text] [Related]
10. Relationship between ras oncogene expression and clinical and pathological features of colonic carcinoma.
Michelassi F; Grad G; Erroi F; Roncella M; Romagnoli J; Handcock M
Hepatogastroenterology; 1990 Oct; 37(5):513-6. PubMed ID: 2253930
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of ras p21 oncoprotein in undifferentiated and well-differentiated epithelial carcinomas of the human ovary.
Kuwashima Y; Shisa H; Uehara T; Kurosumi M; Kobayashi Y; Tanuma J; Shiromizu K; Matsuzawa M; Kishi K
Anticancer Res; 1995; 15(6B):2847-50. PubMed ID: 8669877
[TBL] [Abstract][Full Text] [Related]
12. Comparative immunohistochemical reactivity of monoclonal and polyclonal antibodies to H-ras p21 in normal and neoplastic tissues of rodents and humans.
Ward JM; Perantoni AO; Santos E
Oncogene; 1989 Feb; 4(2):203-13. PubMed ID: 2648257
[TBL] [Abstract][Full Text] [Related]
13. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract][Full Text] [Related]
14. Tamm-Horsfall protein in human renal tumours.
Costello CB; Jasani B; Kumar S
Anticancer Res; 1991; 11(6):2159-61. PubMed ID: 1663721
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining of ras oncogene product in neoplastic and non-neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras.
Ramael M; Deblier I; Eerdekens C; Lemmens G; Jacobs W; Van Marck E
J Pathol; 1993 Apr; 169(4):421-4. PubMed ID: 8501538
[TBL] [Abstract][Full Text] [Related]
16. [Quantitative studies of oncogene ras P21 and P53 gene protein expression in the benign and malignant pleomorphic adenomas of salivary gland].
Wang J; Dong F; Wang X
Zhonghua Kou Qiang Yi Xue Za Zhi; 1997 Jul; 32(4):208-11. PubMed ID: 10680505
[TBL] [Abstract][Full Text] [Related]
17. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
[TBL] [Abstract][Full Text] [Related]
18. Activated Val-12 ras p21 in cell culture fluids and mouse plasma.
Hamer PJ; La Vecchio J; Ng S; DeLellis R; Wolfe H; Carney WP
Oncogene; 1991 Sep; 6(9):1609-15. PubMed ID: 1923528
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the ras and myc oncoproteins in benign gastric lesions.
Karayiannis M; Yiagnisis M; Papadimitriou K; Field JK; Spandidos DA
Anticancer Res; 1990; 10(5A):1127-33. PubMed ID: 2241094
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype, ras oncogenes and p53 onco-suppressor gene in benzo(a)pyrene induced malignant soft tissue tumours in Wistar rats.
Stefanou DG; Nonni AV; Kalpouzos G; Evangelou A; Agnantis NJ
In Vivo; 1998; 12(5):511-21. PubMed ID: 9827359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
